Integrating New Advances into Community Oncology Practice — Ovarian and Endometrial Cancer

Faculty

Faculty

Farrukh T Awan

MD, MS, MBA

Harold C Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas

Professor of Internal Medicine, Associate Director, Section of Hematologic Malignancies/Transplantation and Cellular Therapies, Director of Lymphoid Malignancies Program

Faculty

Samuel J Klempner

MD

Massachusetts General Hospital, Boston, Massachusetts

Program Director, Gastroesophageal Cancers, Tobins Family Endowed Chair in Esophagogastric Cancer

Harvard Medical School, Boston, Massachusetts

Associate Professor

Faculty

Ann LaCasce

MD, MMSc

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts

Associate Professor, Hematology and Medical Oncology, Program Director, Dana-Farber/MGB Fellowship in Hematology/Oncology

Moderator

Stephen "Fred" Divers

MD

American Oncology Network, Hot Springs, Arkansas

Chief Medical Officer

Community Oncology Alliance Hot Springs, Arkansas

Board Executive

Faculty

Shannon N Westin

MD, MPH, FASCO, FACOG

The University of Texas MD Anderson Cancer Center, Houston, Texas

Professor, Medical Director, Gynecologic Oncology Center, Director, Early Drug Development, Department of Gynecologic Oncology and Reproductive Medicine

Faculty

Stephen V Liu

MD

Georgetown University Hospital, Washington, DC

Chief of the Division of Hematology and Oncology, Associate Professor of Medicine

TARGET AUDIENCE
This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, surgeons, radiation oncologists, pharmacists, nurse practitioners, clinical nurse specialists and other healthcare professionals involved in the treatment of cancer.

LEARNING OBJECTIVES

• Appraise the clinical relevance of recent pivotal cancer research published in peer-reviewed journals or presented at major oncology conferences.
• Recall ongoing clinical trials in select hematologic cancers and solid tumors, and as appropriate, refer patients for participation.
• Incorporate individual preferences, tumor biomarkers and other treatment-related factors in personalizing therapy for patients with cancer.
• Educate patients with hematologic cancers or solid tumors about the benefits and risks of novel therapeutic agents and strategies.
• Apply an awareness of new datasets and the perspectives of tumor-specific clinical investigators to refine or validate treatment algorithms.
• Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider the implications for clinical practice.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 4.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
To receive credit for this activity, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Awan — Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, DAVA Oncology, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Invivyd, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Miltenyi Biotec, Pierre Fabre; Contracted Research: Actinium Pharmaceuticals Inc, Pharmacyclics LLC, an AbbVie Company; Data and Safety Monitoring Boards/Committees: Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Caribou Biosciences Inc.

Dr Klempner — Advisory Committees: Astellas, AstraZeneca Pharmaceuticals LP, BeOne, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology, EsoBiotec, Gilead Sciences Inc, I-Mab Biopharma, Jazz Pharmaceuticals Inc, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Signet Therapeutics, Taiho Oncology Inc; Consulting Agreements: Astellas; Contracted Research: Arcus Biosciences, AstraZeneca Pharmaceuticals LP, I-Mab Biopharma, Mersana Therapeutics Inc, Parabilis Medicines; Data and Safety Monitoring Boards/Committees: Sanofi; Stock Options — Private Companies: MBrace Therapeutics; Nonrelevant Financial Relationships: Debbie’s Dream Foundation, Degregorio Family Foundation, Gastric Cancer Foundation, National Cancer Institute/National Institutes of Health, NCCN (member of Gastric and Esophageal Guidelines Committees), Stand Up 2 Cancer/AACR, Torrey Coast Foundation.

Dr LaCasce — Advisory Committees: Caribou Biosciences Inc, Genmab US Inc, Kite, A Gilead Company; Consulting Agreements: Genmab US Inc, Pierre Fabre, Takeda Pharmaceuticals USA Inc.

Dr Liu — Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, Ellipses Pharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Jazz Pharmaceuticals Inc, Johnson & Johnson, Merck, Merus, Natera, Novartis, Nuvalent, OSE Immunotherapeutics, Pfizer Inc, PharmaMar, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, SystImmune Inc, Takeda Pharmaceuticals USA Inc, Yuhan Corporation; Contracted Research: AbbVie Inc, Alkermes, Amgen Inc, AstraZeneca Pharmaceuticals LP, Avenzo Therapeutics, BioNTech SE, Cogent Biosciences, Duality Biologics, Ellipses Pharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, Henlius, MediLink Therapeutics, Merck, Merus, Nuvalent, Nuvation Bio Inc, OSE Immunotherapeutics, Puma Biotechnology Inc, Synthekine, SystImmune Inc.

Dr Westin — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Eisai Inc, Faeth Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, GSK, Immunocore, ImmunoGen Inc, Incyte Corporation, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mereo BioPharma, NGM Biopharmaceuticals, Nuvectis Pharma Inc, Ottimo Pharma, Pfizer Inc, pharmaand GmbH, PMV Pharma, Seagen Inc, Verastem Inc, Zentalis Pharmaceuticals, ZielBio; Contracted Research: AstraZeneca Pharmaceuticals LP, Avenge Bio, Bayer HealthCare Pharmaceuticals, Bio-Path Holdings Inc, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Genmab US Inc, GSK, Jazz Pharmaceuticals Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mereo BioPharma, Novartis, Nuvectis Pharma Inc, Pfizer Inc, pharmaand GmbH, Verastem Inc, Zentalis Pharmaceuticals.

MODERATOR — Dr Divers — Advisory Committees: Daiichi Sankyo Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AbbVie Inc, Astellas, AstraZeneca Pharmaceuticals LP, BeOne, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Genmab US Inc, Jazz Pharmaceuticals Inc, and Lilly.

Release date: September 2026
Expiration date: September 2027

Colombo N et al. Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): A multicentre, randomised, double-blind, phase 3 study. Lancet 2026;407(10538):1525-37. Abstract

Eskander RN et al. Updated overall survival analysis and examination of subsequent therapy in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG-GY018 trial. ASCO 2026;Abstract 5502.

Eskander RN et al. Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: Overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial. Nat Med 2025;31(5):1539-46. Abstract

Gilbert L et al. Overall survival subgroup analyses for prior taxane use in the phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023). ASCO 2026;Abstract 5503.

Lorusso D et al. Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): A phase 3 randomised controlled trial. Lancet 2026;407(10538):1513-24. Abstract

Mileshkin L et al. Updated safety and efficacy of puxitatug samrotecan (Puxi-Sam, AZD8205) in patients (pts) with endometrial cancer (EC) or ovarian cancer (OC): Phase 1/2a BLUESTAR study. ASCO 2026;Abstract 5515.

Piek JM et al. Opportunistic salpingectomy for prevention of tubo-ovarian carcinoma: The European Society of Gynaecological Oncology consensus statements. JAMA 2026;335(10):894-902. Abstract

Powell MA et al. Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial. Gynecol Oncol 2026 (online ahead of print). Abstract

Powell MA et al. Long-term survival rates and cure modeling with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. ASCO 2026;Abstract 5501.

Westin SN et al. Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: The phase III DUO-E trial. J Clin Oncol 2024;42(3):283-99. Abstract